Article

Osteosarcoma Anatomic and Histologic Variants

Department of Pathology, University of Alabama at Birmingham and the Birmingham Veterans Affairs Medical Center 35233, USA.
American Journal of Clinical Pathology (Impact Factor: 3.01). 05/2006; 125(4):555-81. DOI: 10.1309/UC6K-QHLD-9LV2-KENN
Source: PubMed

ABSTRACT Osteosarcoma is the most common primary tumor of bone, yet its absolute incidence among malignant tumors is low. Within its strict histologic definition, osteosarcoma comprises a family of lesions with considerable diversity in histologic features and grade. Its prognosis is dependent not only on these parameters, but also on its anatomic site. It may occur inside the bones (in the intramedullary or intracortical compartment), on the surfaces of bones, and in extraosseous sites. Information of diagnostic or prognostic significance has not been elucidated from studies of its cytogenetics. This review summarizes the anatomic and histologic variations of osteosarcoma and offers a schema for its subclassification.

Download full-text

Full-text

Available from: Gene P Siegal, Aug 02, 2015
2 Followers
 · 
350 Views
  • Source
    • "Osteosarcoma is a primary mesenchymal tumor characterized histologically by malignant tumor cells that directly produce osteoid or immature bone (Resnick et al., 2005; Klein et al., 2006). It has become one of the most common primary malignant bone tumors in childhood and adult (Eppert et al., 2005; Tan et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs have been demonstrated to regulate proliferation and apoptosis in many types of cancers, but biological functions in osteosarcomas remain relatively unknown. Here, we found expression of miR-802 to be up-regulated in osteosarcoma tissues in comparison with adjacent normal tissues. Enforced expression of miR-802 was able to promote cell proliferation in U2OS and MG63 cells, while miR-802 antisense oligonucleotides (antisense miR-802) inhibited cell proliferation. At the molecular level, our results further revealed that expression of p27, a negative cell-cycle regulator, was negatively regulated by miR-802. Therefore, the data reported here indicate that miR-802 is an important regulator in osteosarcoma, our findings contributing to a better understanding of important mis-regulated miRNAs in this tumour type.
    Asian Pacific journal of cancer prevention: APJCP 12/2013; 14(12):7081-4. DOI:10.7314/APJCP.2013.14.12.7081 · 2.51 Impact Factor
  • Source
    • "In our case, the patient was younger than the mean age of occurrence for jaw osteosarcomas. Also, the tumor ran a very aggressive biologic course, a feature uncommon for gnathic lesions [16]. Local recurrence and metastasis occur frequently in patients with osteosarcoma. "
    [Show abstract] [Hide abstract]
    ABSTRACT: An aggressive and fatal case of osteosarcoma of the mandible in a 19-year-old female is reported. Six weeks after the clinical appearance of the swelling, the patient died. This paper is unique in that the age of occurrence and the biologic behavior of the tumor were not consistent with the reported literature. The case report is followed by a brief review of osteosarcoma of the jaw with a note on its clinical presentation, diverse radiologic appearance, varied histopathologic picture, and prognosis.
    11/2012; 2012:635062. DOI:10.1155/2012/635062
  • Source
    • "The disease is seen globally and more frequently in males compared to females (Stiller et al., 2006), but is observed earlier in females correlating to growth spurts. Osteosarcoma diagnosed during the first two decades of life is often poorly differentiated, and cells from these tumors have characteristics of early osteoprogenitor or mesenchymal progenitor cells (Dahlin, 1988; Huvos, 1993; Hopyan et al., 1999; Klein and Siegal, 2006). Correlations between early markers of osteogenesis in conventional osteosarcoma with periods of rapid cell division infer that the disease may be associated with defects in osteoblast differentiation. "
    Osteosarcoma, 04/2012; , ISBN: 978-953-51-0506-0
Show more